TickerFacts.

Compare

Amarin Corp PLC vs Vanda Pharmaceuticals Inc. vs IDEAYA Biosciences, Inc. vs Puma Biotechnology, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAmarin Corp PLC
AMRN		Vanda Pharmaceuticals Inc.
VNDA		IDEAYA Biosciences, Inc.
IDYA		Puma Biotechnology, Inc.
PBYI
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$213.65M$216.10M$218.71M$228.37M
Revenue growth (YoY)-6.5%+8.7%n/m-0.9%
Gross margin56.6%n/an/a74.5% (computed)
Operating margin-23.5%-70.0%-72.8%16.3%
Net margin-18.2%-102.0%-52.0%13.6%
Net income-$38.80M-$220.47M-$113.70M$31.11M
EPS (Diluted)-$0.09-$3.74-$1.28$0.61
Operating cash flow$6.73M-$109.44M-$71.10M$41.80M
Free cash flown/a-$110.44M-$73.47M$41.73M
Cash & equivalents$134.66M$84.85M$112.83M$29.64M
Total assets$670.77M$488.95M$1.11B$216.30M
Total liabilities$211.49M$161.76M$86.39M$85.96M
Shareholders' equity$459.28M$327.19M$1.02B$130.34M
Return on year-end equity-8.4%-67.4%-11.1%23.9%
Shares outstanding416.21M59.10M87.80M50.41M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAmarin Corp PLCVanda Pharmaceuticals Inc.IDEAYA Biosciences, Inc.Puma Biotechnology, Inc.
Latest$213.65M
Ended 2025-12-31		$216.10M
Ended 2025-12-31		$218.71M
Ended 2025-12-31		$228.37M
Ended 2025-12-31
1 year earlier$228.61M
Ended 2024-12-31		$198.77M
Ended 2024-12-31		$7.00M
Ended 2024-12-31		$230.47M
Ended 2024-12-31
2 years earlier$306.91M
Ended 2023-12-31		$192.64M
Ended 2023-12-31		$23.39M
Ended 2023-12-31		$235.64M
Ended 2023-12-31
3 years earlier$369.19M
Ended 2022-12-31		$254.38M
Ended 2022-12-31		$50.93M
Ended 2022-12-31		$228.03M
Ended 2022-12-31
4 years earlier$583.19M
Ended 2021-12-31		$268.68M
Ended 2021-12-31		$27.94M
Ended 2021-12-31		$253.16M
Ended 2021-12-31